<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03692767</url>
  </required_header>
  <id_info>
    <org_study_id>CD22 CAR NK-BJZL-01</org_study_id>
    <nct_id>NCT03692767</nct_id>
  </id_info>
  <brief_title>Study of Anti-CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma</brief_title>
  <official_title>An Observational Clinical Study on the Safety and Efficacy of Anti-CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allife Medical Science and Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allife Medical Science and Technology Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-centre, single-arm and open-label study to investigate the safety and
      efficacy of anti CD22 CAR NK cells in patients with relapsed refractory B cell lymphoma.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2019</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of treatment related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>Day 3-Year 2 after injection</time_frame>
    <description>defined as &gt;= Grade 3 signs/symptoms, laboratory toxicities, and clinical events) that are possibly, likely, or definitely related to study treatment</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">9</enrollment>
  <condition>Refractory B-Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Anti-CD22 CAR NK cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Total dose of 50-600 thousand /kg Anti-CD22 CAR NK cells will be administered at day0</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Anti-CD22 CAR NK Cells</intervention_name>
    <description>Anti-CD22 CAR NK Cells injection</description>
    <arm_group_label>Anti-CD22 CAR NK cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. CD19 (+) B cell lymphoma confirmed by pathological immunohistochemistry or flow
             cytometry

          2. Previously accepted ≥ first-line regimen chemotherapy

          3. Unconditional acceptance of hematopoietic stem cell transplantation or recurrence
             after hematopoietic stem cell transplantation

          4. Over 18 years old and under 70 years old

          5. The expected survival period is more than 3 months.

          6. ECOG≤2

          7. Important organ function is satisfied: cardiac ultrasound indicates cardiac ejection
             fraction ≥50%, no abnormal electrocardiogram; blood oxygen saturation ≥90%; creatinine
             clearance ≥40 mL/min; ALT and AST≤3 times normal range, Total bilirubin ≤ 2.0 mg / dL;

          8. Blood routine: Hgb≥80 g/L, ANC≥1×109/L, PLT≥50×109/L;

          9. The pregnancy test for women of childbearing age must be negative; both men and women
             must agree to use effective contraception during the treatment period and for the
             following 1 year.

         10. Measurable target lesion

        Exclusion Criteria:

          1. Patients with extra-medullary relapse

          2. Burkitt's lymphoma/leukemia

          3. Previously received gene product treatment, anti-CD19/anti-CD3 treatment, or any
             anti-CD19 treatment;

          4. Liver and kidney function:

             Total bilirubin &gt; 2 × ULN (Gilbert Syndrome &gt; 3 × ULN) Aspartate aminotransferase
             (AST) and alanine aminotransferase (ALT) &gt; 3 × ULN Serum creatinine clearance &gt;60
             mL/min

          5. Serological examination:

             Absolute neutrophil count (ANC) &lt;0.75×109/L Platelet count (PLT) &lt;50×109/L

          6. Active hepatitis B (HBV-DNA &gt; 1000 copies / mL), hepatitis C, or uncontrolled
             infection

          7. GVHD ≥ 2 or anti-GVHD treatment

          8. IM19 CAR NK cells received allogeneic cell therapy within 6 weeks before infusion,
             such as donor lymphocyte infusion;

          9. Subject received the most recent treatment (release, chemotherapy, or other) less than
             4 weeks

         10. Active CNS disease (tumor cells in CSF, but &lt; 5 WBCs/mL can be included);

         11. Intracranial hypertension or unconsciousness; respiratory failure; diffuse vascular
             internal coagulation

         12. Creatinine &gt; 1.5 times normal upper limit or ALT / AST &gt; 3 times normal upper limit or
             bilirubin &gt; 2 times normal upper limit

         13. New York Heart Association (NYHA) graded above or above

         14. Uncontrollable diabetes

         15. Suffering from other uncontrolled diseases, the researchers believe that it is not
             suitable for joining

         16. Any situation that the investigator believes may increase the risk of the subject or
             interfere with the test results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 28, 2018</study_first_submitted>
  <study_first_submitted_qc>September 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2018</study_first_posted>
  <last_update_submitted>January 29, 2019</last_update_submitted>
  <last_update_submitted_qc>January 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

